The Global Drug Discovery Services Market was valued at USD 21.17 billion in 2023 and is projected to grow from USD 23.94 billion in 2024 to USD 64.04 billion by 2031, exhibiting a CAGR of 15.09% during the forecast period. The market growth is driven by the rising demand for innovative therapeutics, increasing R&D investments, technological advancements, and the growing prevalence of chronic diseases.

Read Complete Report Details: https://www.kingsresearch.com/drug-discovery-services-market-908

Key Market Drivers

1. Rising Prevalence of Chronic Diseases

• Increasing cases of cancer, cardiovascular diseases, and neurological disorders.

• Demand for novel drugs and personalized medicine is driving R&D.

2. Growth in Biopharmaceutical Research & Outsourcing

• Pharma companies are outsourcing drug discovery services to CROs for cost efficiency.

• Expansion of small & mid-sized biotech firms looking for external expertise.

3. Advancements in AI & Computational Drug Discovery

• AI, machine learning, and big data analytics accelerating drug screening & candidate selection.

• Increased adoption of in silico modeling & virtual screening techniques.

4. Rising Government & Private Sector Investments

• Government grants & funding for drug discovery research.

• Private equity investments in biotechnology & pharmaceutical startups.

5. Expanding Role of Contract Research Organizations (CROs)

• Growth of outsourced R&D models for drug discovery.

• Increased partnerships between biotech firms, academic institutions, and CROs.

Market Segmentation

By Therapeutic Area

• Neurology – Driven by rising demand for Alzheimer’s & Parkinson’s drugs.

• Oncology – Largest segment due to high cancer drug R&D investments.

• Digestive System Diseases – Growing focus on gastrointestinal & metabolic disorders.

• Cardiovascular & Respiratory Diseases – Increasing cases of heart diseases & COPD.

• Others – Includes autoimmune diseases, rare diseases, and infectious diseases.

By Process

• Target Identification & Validation

• Hit-to-Lead Identification

• Lead Optimization

• Candidate Validation & Preclinical Studies

By End-User

• Pharmaceutical & Biotech Companies (Largest share)

• Academic & Research Institutes

• Contract Research Organizations (CROs)

By Type

• Medicinal Chemistry

• Biology Services

• Pharmacokinetics & Drug Metabolism Services

By Drug Type

• Small Molecule Drugs (Dominant due to ease of manufacturing & formulation).

• Biologics & Large Molecule Drugs (Growing due to advances in monoclonal antibodies & gene therapies).

Regional Insights

1. North America (Largest Market)

• Strong presence of pharmaceutical giants (Pfizer, Merck, Eli Lilly).

• High R&D investments in drug discovery technologies.

• Growth of AI-driven drug discovery startups.

2. Europe

• Government funding for life sciences research.

• Major CROs like Charles River and Evotec expanding operations.

• Strong presence of academic research institutions & biotech hubs.

3. Asia-Pacific (Fastest Growing Region)

• Rapid expansion of biopharma companies in China, India & South Korea.

• Increasing clinical trials & contract research services.

• Government initiatives supporting drug development infrastructure.

4. Latin America & Middle East

• Growing investments in pharmaceutical R&D in Brazil & UAE.

• Expansion of local drug development & clinical trials.

Competitive Landscape

Key players in the Drug Discovery Services Market include:

• Charles River Laboratories

• Eurofins Scientific

• WuXi AppTec

• Evotec SE

• Thermo Fisher Scientific

• Merck KGaA

• Genscript Biotech Corporation

• Aptuit (Evotec Company)

These companies focus on strategic collaborations, AI-driven drug discovery, and expansion of research capabilities to maintain a competitive edge.

Future Trends & Challenges

Opportunities:

• AI & machine learning to improve drug discovery efficiency.

• Growing focus on personalized medicine & biologics.

• Expansion of gene therapy & regenerative medicine research.

Challenges:

• High cost & complexity of drug discovery.

• Regulatory challenges & clinical trial delays.

• Intellectual property & data security issues in AI-based drug discovery.

Conclusion

The global drug discovery services market is witnessing robust growth, fueled by rising investments in R&D, the expansion of CRO partnerships, and AI-driven advancements. North America and Asia-Pacific remain key markets, while innovations in biologics, AI-based screening, and personalized medicine will shape the future of drug discovery.